#São Paulo #Denmark #Lundbeck #Vyepti #Eptinezumab

Lundbeck's Innovative Migraine Management

At the 2025 International Headache Congress (IHC), H. Lundbeck A/S revealed exciting new findings regarding migraine management, especially focusing on its treatment, Vyepti (eptinezumab). The research presented at this year's congress, which took place from September 10-13 in São Paulo, Brazil, emphasizes Lundbeck's dedication to improving the lives of patients suffering from debilitating migraines.

Key Insights from the Research

Commitments to Evidence-Based Treatment

Lundbeck's commitment to tackling migraines is demonstrated through six impactful presentations at the IHC. Notably, three of these were oral presentations that detailed the effects of eptinezumab and a new treatment under investigation known as Lu AG09222 (an anti-PACAP monoclonal antibody). The findings from the open-label extension of the RESOLUTION trial and primary results from the SUNSET extension trial marked a significant moment for migraine treatment data, showcasing their long-term preventive effectiveness.

First-Time Reveal of Essential Data

This opportunity provided researchers and medical professionals with the first look at significant data from two major trials—the RESOLUTION trial, aimed at chronic migraine patients with medication overuse headache (MOH), and the SUNSET trial, focused on Japanese patients. The RESOLUTION trial's findings highlighted patients treated with eptinezumab experiencing substantial, lasting reductions in monthly migraine days (MMDs) and marked improvements in self-reported outcomes.

For instance, during the RESOLUTION trial, 50% of participants achieved at least a 50% reduction in monthly migraine days, translating to nearly nine fewer migraine days after a 12-week treatment phase, demonstrating the drug's effectiveness in long-term settings. This statistic brings hope to countless individuals battling chronic migraine.

A Closer Look at Trial Results

According to Johan Luthman, EVP and Head of Research Development at Lundbeck, “Migraine is a chronic, disabling disease that disrupts lives and demands a comprehensive, long-term management approach.” He emphasized the need for treatments that provide sustained relief over time, which is evidenced by patients maintaining their positive responses long after initiating eptinezumab treatment.

Additionally, the SUNSET trial illustrated the long-term efficacy and safety of eptinezumab in a population that historically has not had many treatment options, indicating a notable 35.7% of patients achieved a 50% reduction in MMD by the latter stages of the trial.

Tolerability and Patient Response

The data also underscored the favorable tolerability of eptinezumab across both trials, aligning with previous research findings. Lundbeck's focus on enhancing patient quality of life through effective migraine treatments reaffirms their mission to address the complexities of the condition.

Broadening Perspectives on Migraine Suffering

Through insights from real patient experiences shared during the presentations, Lundbeck provided a narrative centered on the profound personal impacts of migraine. The additional research highlighting patient perspectives during the anti-PACAP antibody HOPE trial showcased the interconnectedness of migraine symptomology and overall wellbeing.

The Larger Picture of Migraine's Impact

Migraine is not only a neurological disorder impacting individuals but also a major contributor to lost productivity and quality of life. This condition affects millions; in Europe alone, it costs the economy approximately EUR 18 billion annually, highlighting the urgent need for effective treatments. The psychological toll of persistent migraines can also lead to other complications, including chronic migraine and MOH due to overuse of acute medications, which can create a vicious cycle that further exacerbates conditions.

About Lundbeck and Vyepti

Lundbeck is known for its dedication to improving brain health through innovations in neuropsychiatric conditions. The company has over 70 years of expertise in neuroscience and aims to create meaningful change for individuals afflicted by neurological disorders.

Eptinezumab, which is administered intravenously, was approved by the FDA in 2020 and has transformed treatment strategies for patients with chronic migraines. With the launch of this medication in over 30 markets worldwide, Lundbeck demonstrates both its commitment to care and pioneering research in migraine prevention.

Conclusion

As Lundbeck presents these critical findings at the IHC, it paves the way for enhanced migraine management strategies that prioritize long-term relief for patients. This evolution in treatment holds promise for those enduring the life-altering effects of migraines, reaffirming Lundbeck’s role as a leader in the field.